The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Is The Market Size Of The Pruritus Therapeutic Market Expected To Change Between 2026 And 2030?
The pruritus therapeutic market size has seen strong growth recently. It is forecast to increase from $15.38 billion in 2025 to $16.76 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.0%. Historically, this growth can be attributed to the rising prevalence of dermatological and systemic conditions, expanded use of antihistamines and corticosteroids, the growth of outpatient dermatology services, increased patient awareness of itch-related disorders, and the availability of various therapeutic options.
The pruritus therapeutic market size is anticipated to demonstrate robust expansion over the forthcoming years. It is predicted to reach $24.04 billion by 2030, registering a compound annual growth rate (CAGR) of 9.4%. This projected growth during the forecast period is attributable to escalating investment in new itch-modulating therapies, a heightened focus on individualized pruritus treatment, the broadening of biologic and immunomodulatory drug pipelines, an increasing demand for non-steroidal treatments, and intensified clinical research activities. Significant trends expected in the forecast period encompass the accelerated development of targeted antipruritic drugs, the increasing adoption of combination drug therapies, a growing emphasis on disease-specific pruritus management, the expansion of advanced topical formulations, and a greater commitment to achieving long-term symptom relief.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9925&type=smp
What Drivers Are Expected To Influence The Pruritus Therapeutic Market During The Forecast Period?
The rising occurrence of chronic kidney disease is anticipated to drive expansion in the pruritus therapeutic market over the forthcoming years. Chronic Kidney Disease (CKD) is defined as a persistent condition where the kidneys progressively lose their proper functioning capability, categorized into five stages of severity. Pruritus, commonly referred to as itching, frequently manifests as a symptom of Chronic Kidney Disease (CKD). While the exact mechanisms remain unclear, pruritus in CKD can stem from diverse underlying causes. As an illustration, data from June 2023, provided by Kidney Research UK, a charitable body in the UK dedicated to research and advocacy for kidney diseases, indicated that roughly 7.19 million individuals in the UK suffered from chronic kidney disease in 2023. This figure accounted for over 10% of the UK’s population and is forecast to climb to 7.61 million people by 2033. Consequently, the rising prevalence of chronic kidney disease is a key driver for the pruritus therapeutic market.
How Is The Pruritus Therapeutic Market Structured Across Different Segments?
The pruritus therapeutic market covered in this report is segmented –
1) By Type: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressant, Calcineurin Inhibitors, Others Types
2) By Disease Type: Atopic Dermatitis Or Eczema, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types
3) By Application: External Use, Oral, Injection
4) By End Use: Hospitals, Clinics, Other Uses
Subsegments:
1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids
2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines
3) By Local Anesthetics: Topical Local Anesthetics, Injectable Local Anesthetics
4) By Counterirritants: Menthol-Based Products, Camphor-Based Products
5) By Immunosuppressants: Systemic Immunosuppressants, Topical Immunosuppressants
6) By Calcineurin Inhibitors: Tacrolimus, Pimecrolimus
7) By Other Types: Antidepressants, Phototherapy Treatments, Biologic And Targeted Therapies
What Key Developments And Trends Are Impacting The Pruritus Therapeutic Market?
Leading companies within the pruritus therapeutic market are adopting a strategic partnership approach aimed at treating moderate-to-severe atopic dermatitis. These strategic partnerships involve companies leveraging each other’s strengths and resources to achieve mutual benefits and success. For example, in January 2023, Amgen Inc., a US-based biopharmaceutical company, in collaboration with Kyowa Kirin, is investigating rocatinlimab (AMG 451/KHK4083), a potential first-in-class anti-OX40 monoclonal antibody being studied for those with moderate to severe atopic dermatitis. Amgen and Kyowa Kirin have recently started enrolling participants in a worldwide Phase 3 trial (ROCKET) to assess the safety and effectiveness of rocatinlimab in a diverse population of moderate-to-severe atopic dermatitis patients with a high disease burden. The ROCKET Phase 3 program comprises seven worldwide investigations. Kyowa Kirin Co., Ltd. is a pharmaceutical and biotechnology company based in Japan.
Which Major Players Dominate The Pruritus Therapeutic Market?
Major companies operating in the pruritus therapeutic market are Astellas Pharma Inc., Bristol Myers Squibb Company, Cipla Inc., Eli Lilly And Company, Galderma Laboratories LP, GlaxoSmithKline plc, Merck And Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Abbott Laboratories, Almirall SA, Eisai Co. Ltd., Glenmark Pharmaceuticals Ltd., Ipca Laboratories Ltd., Lupin Chemicals Ltd., Cara Therapeutics Inc., EPI Health LLC, AbbVie Inc., Bayer AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Huapont Life Sciences Co. Ltd., LEO Pharma AS, MC2 Therapeutics Ltd., Novan Inc., Trevi Therapeutics Inc., UCB SA, Viatris Inc., Teva Pharmaceutical Industries Ltd.
Read the full pruritus therapeutic market report here:
https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report
Which Region Is Forecast To Lead The Pruritus Therapeutic Market In Terms Of Market Size?
North America was the largest region in the pruritus therapeutic market in 2025. The regions covered in the pruritus therapeutic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Pruritus Therapeutic Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=9925&type=smp
Browse Through More Reports Similar to the Global Pruritus Therapeutic Market 2026, By The Business Research Company
Pruritus Therapeutics Global Market Report
https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report
Tinea Pedis Treatment Global Market Report
https://www.thebusinessresearchcompany.com/report/tinea-pedis-treatment-global-market-report
Vitiligo Treatment Global Market Report
https://www.thebusinessresearchcompany.com/report/vitiligo-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model